-
公开(公告)号:US11866556B2
公开(公告)日:2024-01-09
申请号:US17166909
申请日:2021-02-03
Applicant: Galderma Holding SA
Inventor: Morgan Karlsson
IPC: C08J3/24 , C08B37/08 , C08L5/08 , A61K8/73 , A61K31/728 , A61K47/36 , A61K9/06 , A61Q19/08 , A61L27/20 , C08J3/075
CPC classification number: C08J3/24 , A61K8/735 , A61K9/06 , A61K31/728 , A61K47/36 , A61L27/20 , A61Q19/08 , C08B37/0072 , C08J3/075 , C08L5/08 , A61K2800/91 , A61L2430/34 , C08J2305/08 , C08L2201/54 , C08L2203/02
Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.
-
公开(公告)号:US20230346680A1
公开(公告)日:2023-11-02
申请号:US18348736
申请日:2023-07-07
Applicant: GALDERMA HOLDING SA
Inventor: Johan Olsson , Morgan Karlsson
Abstract: Described are high molecular weight glycosaminoglycan (GAG) hydrogel compositions comprising GAGs covalently crosslinked with a carbohydrate crosslinker, and methods of making the high molecular weight GAG hydrogel compositions. Further described are methods of using the high molecular weight glycosaminoglycan (GAG) hydrogel compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.
-
公开(公告)号:US20230323041A1
公开(公告)日:2023-10-12
申请号:US18208527
申请日:2023-06-12
Applicant: Galderma Holding SA
Inventor: Johan OLSSON , Craig Steven HARRIS
IPC: C08J3/075 , C08B37/00 , C08B37/08 , C08L5/00 , C08J3/24 , C08L5/08 , C07C209/62 , C07C213/00 , C07C269/06 , C07F7/08 , C08J7/14 , C08K5/09 , A61K8/04 , A61K8/73 , A61Q19/00 , A61K9/00
CPC classification number: C08J3/075 , C08B37/0069 , C08B37/0072 , C08L5/00 , C08J3/24 , C08L5/08 , C08B37/0063 , C07C209/62 , C07C213/00 , C07C269/06 , C07F7/083 , C08J7/14 , C08K5/09 , A61K8/042 , A61K8/73 , A61K8/735 , A61Q19/00 , A61K9/0019 , C08J2305/00 , C08J2305/08 , C07C2603/18
Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
-
公开(公告)号:US20230212360A1
公开(公告)日:2023-07-06
申请号:US18184439
申请日:2023-03-15
Applicant: Galderma Holding SA
Inventor: Hotan MOJARRADI , Johan OLSSON , Craig HARRIS , Jean-Guy BOITEAU , Thibaut GERFAUD , Loïc TOMAS
CPC classification number: C08J3/075 , C08B37/0072 , C08J3/24 , C08J2305/08
Abstract: The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
-
公开(公告)号:US20230211051A1
公开(公告)日:2023-07-06
申请号:US17941713
申请日:2022-09-09
Applicant: Galderma Holding SA
Inventor: Bengt Agerup
Abstract: Particles made of a viscoelastic medium, are injectable gel particles, and have a size, when subjected to a physiological salt solution, in the range of from 1 to 5 mm. The particles are useful in a soft tissue augmentation implant. The implant includes particles of a viscoelastic medium, wherein a major volume of the particles are injectable gel particles The implant is useful in a method of soft tissue augmentation in a mammal, including man, comprising subepidermal administration at a site in said mammal where soft tissue augmentation is desirable, of an implant.
-
公开(公告)号:US11643509B2
公开(公告)日:2023-05-09
申请号:US18071282
申请日:2022-11-29
Applicant: Galderma Holding SA
Inventor: Hotan Mojarradi , Johan Olsson , Craig Steven Harris , Jean-Guy Boiteau , Thibaut Gerfaud , Loïc Tomas
IPC: A61K8/04 , A61K8/73 , A61P17/00 , A61Q19/00 , A61K9/00 , C08B37/08 , C08K5/09 , C08K5/08 , C07C209/62 , C07C7/08 , C07C213/00 , C08J3/24 , C08J3/075 , C08L5/00 , C08J7/14 , C07C269/06 , C08B37/00 , C08L5/08 , C07F7/08
CPC classification number: C08J3/075 , A61K8/042 , A61K8/73 , A61K8/735 , A61K9/0019 , A61Q19/00 , C07C209/62 , C07C213/00 , C07C269/06 , C07F7/083 , C08B37/0063 , C08B37/0069 , C08B37/0072 , C08J3/24 , C08J7/14 , C08K5/09 , C08L5/00 , C08L5/08 , C07C2603/18 , C08J2305/00 , C08J2305/08
Abstract: The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
-
公开(公告)号:US20230029456A1
公开(公告)日:2023-02-02
申请号:US17757734
申请日:2020-12-19
Applicant: GALDERMA HOLDING SA , IPSEN BIOPHARM LIMITED
Inventor: Ulf STAHL , Peter FRANK , Anders JARSTAD , Sebastiaan MUL , John NOLIN , Lena NODQVIST , Simon ABERG
IPC: C12N9/52
Abstract: The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (˜150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (˜150 kDa) in solution, without the need for reconstitution by the end user.
-
公开(公告)号:US11458226B2
公开(公告)日:2022-10-04
申请号:US16593941
申请日:2019-10-04
Applicant: GALDERMA HOLDING SA
Inventor: Bengt Ågerup
Abstract: Particles made of a viscoelastic medium, are injectable gel particles, and have a size, when subjected to a physiological salt solution, in the range of from 1 to 5 mm. The particles are useful in a soft tissue augmentation implant. The implant includes particles of a viscoelastic medium, wherein a major volume of the particles are injectable gel particles The implant is useful in a method of soft tissue augmentation in a mammal, including man, comprising subepidermal administration at a site in said mammal where soft tissue augmentation is desirable, of an implant.
-
公开(公告)号:US11376369B2
公开(公告)日:2022-07-05
申请号:US16066900
申请日:2016-12-21
Applicant: Galderma Holding SA
Inventor: Anders Holmqvist , Max Blomqvist , Jonas Törnsten
Abstract: A syringe including a barrel, a plunger moveably arranged within said barrel, and a plunger rod for driving said plunger. A first engagement member is arranged at the plunger rod, such that a longitudinal movement of the plunger rod yields a rotational movement of said first engagement member. The first engagement member includes a grooved surface. A second engagement member is arranged at the barrel to engage with said grooved surface of the first engagement member, wherein the first engagement member is arranged to move relative to the second engagement member, such that feedback is given to a user as the plunger rod is moved relative to the barrel for driving said plunger. The first engagement member is arranged at said plunger rod with a predetermined play there between.
-
公开(公告)号:US20220133951A1
公开(公告)日:2022-05-05
申请号:US17576675
申请日:2022-01-14
Applicant: Galderma Holding SA
Inventor: Peter MORGAN , Lubica MACAKOVA
IPC: A61L27/18 , A61K8/02 , A61K8/04 , A61K8/20 , A61K8/73 , A61K8/85 , A61K8/86 , A61L2/04 , A61L2/08 , A61L27/02 , A61L27/20 , A61L27/52 , A61L27/54 , A61L27/58 , A61Q19/08 , C08L1/28 , C08L67/04 , C08L71/00
Abstract: Described are ready-to-use injectable compositions comprising polymeric microspheres or microparticles of non-animal origin, a hydrogel comprising water and a cellulose-derivative gelling agent, and polysorbate 80. Further described are methods of using the ready-to-use injectable compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.
-
-
-
-
-
-
-
-
-